Cardiovascular drugs and analysis of potential risk factors associated with mortality in severe coronavirus disease 2019 patients
Rev. Assoc. Med. Bras. (1992, Impr.)
;
68(2): 176-182, Feb. 2022. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-1365356
ABSTRACT
SUMMARY OBJECTIVES:
Cardiovascular diseases are also considered to increase the risk of death in COVID-19 patients. However, real-world data concerning the risk factors for death in patients with severe COVID-19 still remain vague. This study aimed to identify the potential risk factors associated with mortality in severe COVID-19 patients.METHODS:
All consecutive patients admitted to the intensive care unit (ICU) of our institute for COVID-19 for severe COVID-19 pneumonia from April 1, 2020 to July 20, 2020 were included in the analysis. Patient characteristics, including complete medical history and comorbid diseases, blood test results during admission and on day 7, and clinical characteristics were compared between survivors and nonsurvivors.RESULTS:
There was no significant difference between survivors and nonsurvivors regarding age, gender, and preexisting cardiovascular diseases. Moreover, the rate of the medications including angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blockers did not differ between survivors and nonsurvivors. The peak C-reactive protein (CRP), procalcitonin, fibrinogen, and d-dimer levels and the rate for chronic renal failure were significantly higher in nonsurvivors compared with survivors. Intubated patients had a higher risk of death than the others had.CONCLUSIONS:
This study failed to demonstrate a significant difference in preexisting cardiovascular diseases and cardiovascular medications between survivors and nonsurvivors who were admitted to ICU for severe COVID-19. Our findings indicate that the presence of chronic renal failure, a high peak ferritin concentration, and the need for invasive mechanical ventilation appear predictive for mortality. We propose that these risk factors should be taken into account in defining the risk status of severe COVID-19 patients admitted to the ICU.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Fármacos Cardiovasculares
/
COVID-19
Tipo de estudo:
Estudo de etiologia
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. Assoc. Med. Bras. (1992, Impr.)
Assunto da revista:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
Medicina
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
Turquia
Instituição/País de afiliação:
İstanbul Atlas University/TR
/
Bayrampaşa Kolan Hospital/TR
/
University of Health Sciences/TR
/
Van Yuzuncu Yil University/TR
Similares
MEDLINE
...
LILACS
LIS